Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Palbociclib Related Intermediates: Palbociclib CAS 571190-30-2 5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7 tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4| Item | Specifications |
| Appearance | Light Brown to Brown Powder |
| Purity / Analysis Method | >98.0% (HPLC) |
| LCMS | Consistent With Structure |
| Loss on Drying | <1.00% |
| Total Impurities | <2.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Palbociclib (CAS: 571190-30-2) |
Description:
Specifications:
Package & Storage:
| Chemical Name | tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate |
| Synonyms | 1-Boc-4-(6-Nitro-3-Pyridyl)piperazine; 4-(6-Nitro-3-pyridinyl)-1-Piperazinecarboxylic Acid tert-Butyl Ester; tert-Butyl 4-(6-Nitro-3-Pyridinyl)-1-Piperazinecarboxylate |
| CAS Number | 571189-16-7 |
| CAT Number | RF-PI1850 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C14H20N4O4 |
| Molecular Weight | 308.33 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (CAS: 571189-16-7) is an intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib blocks cell cycle progression from phase G1 into S by inhibiting CDK4/6-dependent retinoblastoma (RB) phosphorylation. Palbociclibhas been used for the treatment of HER2 negative, estrogen receptor (ER) positive metastatic breast cancer.
